



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q3

2025

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO
ANDREAS LÖSLER, CFO

October 30, 2025

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q3 2025

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Alzchem with further growth in sales and EBITDA




Revenue above previous year:
+ 2% for 9m
+ 6% for Q3



Outlook confirmed;
Sales and EBITDA
expected to be on record
level in 2025



EBITDA margin with
further improvements
up to 20.3%



New creatine facility
successfully
commissioned



Cooperation with
Ehrmann – Creavitalis®
goes to supermarket



Specialty Chemicals
segment pushes
growth:
+9% revenue growth
+16% EBITDA growth



Update on
Nitroguanidine expansion

- ✓ Construction activities for Nitroguanidine expansion in Germany are on schedule and within budget; buildings are almost completed
- ✓ Commissioning expected in Q3 2026 – ahead of customer expansion
- ✓ Site selection for US expansion ongoing - Clear favorites are starting to emerge



Creatine in Everyday Nutrition – A New Application successfully implemented

- Creavitalis® – premium creatine “Made in Germany” – enters the functional food segment for the first time
- Three product categories
 - **High Protein Creatine Pudding** (Chocolate, White Choc)
 - **High Protein Creatine Drink** (Chocolate, Pistacia)
 - **High Protein Creatine Bar** (Peanut Caramel Choc, White Choc Strawberry)
- **Availability:**
 - **All major German supermarket chains**
 - **Country: Germany;** next steps: Netherlands, Finland, Poland, Czech Republic, Slovakia, United Kingdom, Spain, Portugal
 - Ehrmann’s online shop



A Milestone for Creavitalis®

This partnership opens the food market as a new application area for creatine and positions Creavitalis® as a visible, enjoyable and scientifically backed ingredient in modern nutrition.

Alzchem develops Creatine–Protein Concept	Initial contact	Extensive series of trials	First production run	Market launch
		Stability testing at Alzchem		
		Several technical and commercial meetings		
10/2025				

AGENDA – ANALYST PRESENTATION Q3 2025

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)



Sales and EBITDA reductions on expected level


SALES




EBITDA



SALES



EBITDA




SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	+ 0.4%	- 7.6%
Price	+ 5.6%	- 0.5%
Currency	- 0.3%	+ 0.1%

COMMENTS

- 9m with sales decline of 8% on expected level; mainly resulting from reduced quantities
- Most impact from ongoing weak economics within metallurgical sector in the European steel market
- Q3 stand alone with increased sales and EBITDA supported by agriculture business and new product launch within NITRALZ® business
- Electricity costs still higher compared to last year with adverse cost effect on EBITDA
- Inventory level on expected high level in preparation for longer maintenance shut down of carbide furnace in 2026



CREAMINO

Dormex[®]

Bioselect[®]

DYHARD[®]

Creapure[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)


Segments growth trend continued




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	+ 3.0%	+ 7.3%
Price	+ 7.1%	+ 2.1%
Currency	- 1.8%	- 0.7%

COMMENTS

- The substantial growth in sales and EBITDA was mainly attributed to:
 - **Human Nutrition** – Growing demand of Creapure® and Creavitalis®
 - **Custom Manufacturing** – Upward trend within the German and European chemical industries
- All other products showed moderate growth or stable development
- Positive development in the quarterly comparison is mainly driven by the sectors human nutrition and defense
- New creatine capacity has been successfully commissioned



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Regulated grid fees impact sales and result




SALES




EBITDA



SALES



EBITDA



COMMENTS

- Slight reduction in sales development compared to the previous year
- Decreased regulated electricity grid fees for chemical park customers
- EBITDA development mainly resulting from reduced grid fee charges to customers

FINANCIAL OVERVIEW

Robust growth in EBITDA and earnings



Alzchem Group	Q3 2024	Q3 2025	qoq %	2024 1 - 9	2025 1 - 9	yoy %
SALES (in M€)	128.9	137.3	+6.5%	415.2	424.8	+2.3%
EBITDA (in M€)	24.9	29.7	+19.5%	76.8	86.2	+12.2%
EBITDA margin (in %)	19.3%	21.7%	+2.4 pp	18.5%	20.3%	+1.8 pp
Earnings per Share (in €)	1.22	1.61	+32.6%	3.83	4.62	+20.6%

- Sales slightly above prior year period and with 6.5% increase for Q3 stand alone
- Specialty Chemicals segment offsets declines in other segments – volume and price growth on group level
- High utilization rate leads to improved cost ratio on production level and compensates for increased energy prices
- Personnel expenses impacted by collective wage increases and slightly higher FTE following the growth and preparation for NQ commissioning
- Increased sales portion of Specialty Chemicals and higher sales in US support increase in EBITDA as well as EBITDA-margin
- Improved financial result supports positive development in net result

SALES ANALYSIS	DELTA Q3	DELTA 01 - 09
Volume	+1,3%	+1,4%
Price	+6,4%	+1,3%
Currency	-1,2%	-0,4%

BALANCE SHEET & CASHFLOW

Financial situation at positive net cash; increase in total assets



Balance sheet KPIs (T€)	31.12.2024	30.09.2025	Deviation	
Balance sheet total	483,826	589,454	105,628	21.8%
Inventories	101,166	118,512	17,346	17.1%
Equity	207,471	235,730	28,259	13.6%
Equity ratio	42.9%	40.0%	-2.9 pp	
Liabilities to Banks	48,671	42,693	- 5,978	-12.3%
Cash and cash equivalents	61,544	79,552	18,008	29.3%
Net financial debt (-) / asset (+)	12,873	36,859	23,986	186.3%

Cashflow KPIs (T€)	1 - 9 2024	1 - 9 2025	Deviation	
Operating Cashflow	75,084	115,497	40,413	53.8%
Investing Cashflow	- 26,364	- 67,430	- 41,066	155.8%
Free Cashflow	48,720	48,067	- 653	-1.3%
Financial Cashflow	- 19,902	- 29,404	- 9,502	47.7%
Net increase in cash	28,819	18,663	- 10,155	-35.2%

COMMENTS

- Increase in balance sheet total resulting from increased CAPEX and customer grants
- Planned inventory increase in preparation for carbide furnace maintenance
- Alzchem still shows net financial assets
- Customer grants for Nitroguanidine expansion led to a stable operating cashflow despite increased working capital
- Investing cashflow highly above prior year as Nitroguanidine expansion is on schedule
- Higher dividend payments and share buyback program influence financing cash flow
- Pension obligation on reduced level as interest rates increased to 3.8% with positive impact on equity ratio

KPI impact of nitroguanidine expansion 1-9/2025 in M€




OUTLOOK 2025 (in M€)


The forecast remains valid – Growth in sales and EBITDA



SALES



EBITDA



COMMENTS

- Outlook for 2025 confirmed
- Major assumptions are still valid
 - No global recession; stable world economy with raw material and logistics costs remain at current levels
 - Electricity prices stay high
 - No major impacts from the US tariffs policy and no further weakening of US-Dollar
- Sales Growth
 - Organic growth, no acquisitions
 - Specialty Chemicals: Growth mainly through increased volumes of Creapure®, Creamino® and Nitroguanidin
 - Basics & Intermediates: Slight sales decline expected, mainly due to metallurgy / steel industry; Positive trends for NITRALZ®
 - Capacity expansion for Nitroguanidin has no significant impact on 2025 sales
- EBITDA Growth
 - Further increase in higher-margin Specialty Chemical sales will increase EBITDA as well

FINANCIAL CALENDAR

Upcoming dates*



NOV 12	2025	Berenberg Pan-European Discovery Conference USA (virtual)
NOV 13	2025	MKK – Münchner Kapitalmarkt Konferenz
NOV 24 – 25	2025	Deutsches Eigenkapitalforum
DEC 2	2025	Berenberg European Conference
JAN 19	2026	Kepler Cheuvreux & UniCredit Conference
FEB 5	2026	Montega HIT Conference
FEB 27	2026	Annual Report 2025
MAR 5	2026	Berenberg EU Opportunities Conference
APR 30	2026	Quarterly Statement 1st Quarter 2026
MAY 5	2026	Annual General Meeting 2026
MAY 21	2026	Berenberg European Conference Manhattan
JUL 30	2026	Half-year Financial Report 2026
OCT 29	2026	Quarterly Statement 3rd Quarter 2026

*subject to change

**ALL DATES AT A
GLANCE**

 [Financial calender](#)



FEEDBACK

We appreciate your feedback



Were your expectations met?

Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

[Link](#)

QR-Code



**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q3 2025

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group



ALZCHEM GROUP (IN T€)


	31.12.2024	30.09.2025	Deviation	
Intangible assets	3,671	3,562	-109	-3.0%
Tangible assets	192,976	236,705	43,729	22.7%
Investment properties				
Right of use (assets)	4,023	3,240	-783	-19.5%
Investments accounted for using the equity method				
Financials assets	6	6		
Trade receivables				
Other receivables	1,235	18,487	17,252	>1.000%
there of Deferred tax assets for pensions provisions				
Deferred tax assets	20,121	17,378	-2,743	-13.6%
SUM NON-CURRENT ASSETS	222,031	279,378	57,347	25.8%
Inventories	101,166	118,512	17,346	17.1%
Trade receivables	78,935	74,049	-4,886	-6.2%
Financial assets		0	0	
Other receivables	20,080	37,939	17,859	88.9%
Income tax receivables	71	24	-47	-66.3%
Cash and cash equivalents	61,544	79,552	18,008	29.3%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	261,795	310,076	48,281	18.4%
SUM ASSETS	483,826	589,454	105,628	21.8%

ALZCHEM GROUP (IN T€)

	31.12.2024	30.09.2025	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	186,843	215,373	28,530	15.3%
Other comprehensive income	-18,080	-14,873	3,207	-17.7%
Own shares	-1,512	-5,117	-3,605	238.5%
SHARE TO THE SHAREHOLDERS	205,536	233,667	28,131	13.7%
Non-controlling interests	1,934	2,063	128	6.6%
SUM EQUITY	207,471	235,730	28,259	13.6%
Provisions for pensions	96,937	91,991	-4,946	-5.1%
Other provisions	22,209	21,853	-356	-1.6%
Loans	41,082	36,333	-4,750	-11.6%
Finance lease liabilities	2,326	1,606	-720	-31.0%
Trade liabilities		14	14	
Contract liabilities		85,063	85,063	
Other liabilities	647	484	-164	-25.3%
Deferred tax liabilities	7,755	8,232	478	6.2%
SUM NON-CURRENT LIABILITIES	170,956	245,576	74,620	43.6%
Other provisions	3,413	2,444	-969	-28.4%
Loans	7,589	6,360	-1,228	-16.2%
Finance lease liabilities	1,826	1,766	-60	-3.3%
Finance liabilities	1,994		-1,994	-100.0%
Trade liabilities	37,425	42,463	5,038	13.5%
Contract liabilities		1,113	1,113	
Other liabilities	39,974	44,249	4,274	10.7%
Income tax liabilities	13,178	9,753	-3,426	-26.0%
SUM CURRENT LIABILITIES	105,399	108,147	2,748	2.6%
Sum EQUITY AND LIABILITIES	483,826	589,454	105,628	21.8%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Interest rates increased from 3.4% to 3.8%
- Pension payments develop as expected with 2.0M€ - pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Deviation (Q3)	
Revenue	150,064	136,191	128,937	139,040	144,680	142,879	137,266		8,329	6%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	-6,521	12,682	-4,310	-7,169	11,436	3,433	624		4,934	-114%
Other income	3,558	3,731	3,716	6,295	5,263	5,006	3,806		90	2%
Raw materials and consumables used	-53,237	-57,999	-40,548	-43,880	-64,236	-47,293	-43,769		-3,221	8%
Employee benefits expense	-40,589	-42,468	-38,100	-39,343	-41,150	-44,894	-43,245		-5,146	14%
Other expense	-28,367	-25,118	-24,813	-26,488	-28,632	-30,036	-24,957		-144	1%
EBITDA	24,910	27,021	24,883	28,455	27,362	29,096	29,724		4,841	19%
Depreciation expense	-6,534	-6,453	-6,402	-6,928	-6,552	-6,435	-6,655		-253	4%
Impairment										
EBIT	18,375	20,567	18,480	21,527	20,810	22,662	23,069		4,589	25%
Investment income										
Other interest and similar income	292	687	450	801	712	626	819		369	82%
Other interest and similar expense	-1,454	-1,366	-1,537	-1,480	-1,278	-1,284	-1,254		283	-18%
Financial result	-1,162	-679	-1,087	-679	-567	-658	-436		652	-60%
Result from associates										
Result from ordinary business	17,213	19,888	17,393	20,848	20,243	22,003	22,634		5,241	30%
Taxes on income and profit	-4,977	-5,460	-4,974	-5,685	-5,607	-6,128	-6,297		-1,323	27%
<i>thereof income tax</i>	-4,463	-5,036	-4,473	-6,148	-4,537	-6,330	-5,550		-1,077	24%
<i>thereof change from deferred taxes</i>	-514	-424	-501	463	-1,070	202	-748		-246	49%
Annual result	12,237	14,428	12,419	15,163	14,636	15,876	16,337		3,918	32%
<i>thereof minority interests</i>	43	43	43	43	43	43	43			
<i>thereof shares held by shareholders</i>	12,194	14,385	12,376	15,120	14,594	15,833	16,294		3,918	32%
Result per share in EUR	1.20 €	1.41 €	1.22 €	1.49 €	1.44 €	1.57 €	1.61 €			

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

Revenue	
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	
Other income	
Raw materials and consumables used	
Employee benefits expense	
Other expense	
EBITDA	
Depreciation expense	
Impairment	
EBIT	
Investment income	
Other interest and similar income	
Other interest and similar expense	
Financial result	
Result from associates	
Result from ordinary business	
Taxes on income and profit	
<i>thereof income tax</i>	
<i>thereof change from deferred taxes</i>	
Annual result	
<i>thereof minority interests</i>	
<i>thereof shares held by shareholders</i>	
Result per share in EUR	

Q3 2024	Q3 2025	Deviation (QoQ)	
128,937	137,266	8,329	6.5%
-4,310	624	4,934	-114.5%
3,716	3,806	90	2.4%
-40,548	-43,769	-3,221	7.9%
-38,100	-43,245	-5,146	13.5%
-24,813	-24,957	-144	0.6%
24,883	29,724	4,841	19.5%
-6,402	-6,655	-253	3.9%
0	0	0	
18,480	23,069	4,589	24.8%
0	0	0	
450	819	369	81.9%
-1,537	-1,254	283	-18.4%
-1,087	-436	652	-59.9%
0	0	0	
17,393	22,634	5,241	30.1%
-4,974	-6,297	-1,323	26.6%
-4,473	-5,550	-1,077	24.1%
-501	-748	-246	49.2%
12,419	16,337	3,918	31.5%
43	43	0	0.0%
12,376	16,294	3,918	31.7%
1.22 €	1.61 €	0	32.6%

YTD Sep.2024	YTD Sep.2025	Deviation (YoY)	
415,192	424,825	9,633	2.3%
1,852	15,493	13,642	736.8%
11,006	14,076	3,070	27.9%
-151,783	-155,297	-3,514	2.3%
-121,156	-129,289	-8,133	6.7%
-78,297	-83,625	-5,327	6.8%
76,813	86,183	9,370	12.2%
-19,390	-19,642	-252	1.3%
0	0	0	
57,423	66,541	9,118	15.9%
0	0	0	
1,429	2,156	727	50.8%
-4,358	-3,817	541	-12.4%
-2,928	-1,660	1,268	-43.3%
0	0	0	
54,495	64,880	10,386	19.1%
-15,411	-18,032	-2,621	17.0%
-13,972	-16,416	-2,444	17.5%
-1,439	-1,616	-176	12.2%
39,083	46,849	7,765	19.9%
128	128	0	0.0%
38,955	46,720	7,765	19.9%
3.83 €	4.62 €	1	20.6%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

	Q3 2024	Q3 2025	1 - 9 2024	1 - 9 2025
Consolidated earnings before taxes	17,393	22,634	54,495	64,880
Depreciation on fixed and intangible assets	6,402	6,655	19,390	19,642
Decrease in pension provisions	-547	-612	-1,651	-1,986
Loss (+) / Profit (-) from the sale of non-current assets	36	-1	33	21
Other non-cash income (-) and expenses (+)	1,420	892	9,306	3,161
Financial result	1,087	436	2,928	1,660
Interests & Taxes	-4,788	-4,556	-8,651	-12,442
Increase (+) / Decrease (-) Net Working Capital	-9,748	14,279	-766	-14,977
Payments from customer grants		4,532		55,537
Cashflow from ongoing operations (Net cash flow)	11,255	44,259	75,084	115,497
Cash outflows for investments in fixed assets	-13,892	-26,936	-26,331	-67,471
Cash inflows from the sale of fixed assets	-36	1	-33	41
Cash inflows from grants received for investments				
Cashflow from investing activity	-13,928	-26,935	-26,364	-67,430
Free cashflow	-2,673	17,324	48,720	48,067
Deposits (+) / Repayment (-) bank loans long-term				
Repayment of bank loans long-term	-2,208	-1,583	-6,187	-6,000
Deposits (+) / Repayment (-) from short-term financing lines				
Dividend payments			-12,212	-18,190
Payment of reduction in leasing liabilities	-434	-482	-1,332	-1,438
Payments for the acquisition of own shares (incl. transaction costs)		0		-3,605
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	-2,642	-2,065	-19,902	-29,404
Net increase / decrease in cash and cash equivalents	-5,315	15,259	28,819	18,663

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES


SALES	2023				2024				2025				YTD Q3 2025					
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Deviation PY (Q3)		PY T€	Actual T€	Deviation PY (YOY)	
													T€	%			T€	%
Basics & Intermediates	57,337	46,038	44,271	44,538	49,299	41,848	40,927	41,929	42,638	35,605	43,309		2,382	6%	132,074	121,552	-10,521	-8%
Specialty Chemicals	85,783	73,172	69,545	91,302	92,961	85,805	80,354	88,969	94,512	100,128	86,978		6,624	8%	259,120	281,617	22,497	9%
Other and Holding	7,312	7,389	7,007	6,955	7,804	8,538	7,656	8,142	7,530	7,146	6,979		-677	-9%	23,998	21,655	-2,343	-10%
Group Consolidation																		
Alzchem Group	150,432	126,599	120,824	142,794	150,064	136,191	128,937	139,040	144,680	142,879	137,266		8,329	6%	415,192	424,825	9,633	2%

EBITDA

EBITDA	2023				2024				2025				YTD Q3 2025					
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Deviation PY (Q3)		PY T€	Actual T€	Deviation PY (YOY)	
													T€	%			T€	%
Basics & Intermediates	2,780	2,410	1,065	3,275	1,802	3,055	1,827	4,142	140	1,174	3,754		1,928	106%	6,683	5,068	-1,615	-24%
Specialty Chemicals	16,019	14,936	18,541	23,747	22,684	22,843	21,749	26,741	26,041	27,854	24,117		2,368	11%	67,276	78,012	10,736	16%
Other and Holding	475	438	721	-1,171	537	849	1,114	-711	307	50	596		-518	-46%	2,500	954	-1,546	-62%
Group Consolidation	-357	88	-793	-802	-113	274	194	-1,717	874	18	1,257		1,063	549%	354	2,149	1,794	506%
Alzchem Group	18,917	17,872	19,534	25,049	24,910	27,021	24,883	28,455	27,362	29,096	29,724		4,841	19%	76,813	86,183	9,370	12%

ALZCHEM GROUP LOCATIONS

Production sites and sales companies




"VERBUND" – FULLY INTEGRATED BUSINESS MODEL

Vertically integrated production of chemical products based on the NCN chain



- Segment Specialty Chemicals
- Segment Basics & Intermediates



BENEFITS OF "VERBUND"

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

GLOBAL DEVELOPMENTS AS GROWTH DRIVERS

POPULATION GROWTH

LONGER LIFE EXPECTANCY

CLIMATE CHANGE

SUSTAINABILITY

SAFETY & DEFENCE

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



MAIN PRODUCTS		DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A nutritional additive for poultry and pigs	Feed additive
	Creapure®	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis®	Creatine for health and food applications	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for explosives and agrochemical products	Agriculture, Automotive, Defense

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags. key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	 NITRALZ [®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Eminex [®]	Reduction of methane emissions during storage of manure	Agriculture
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Klüh Catering, VIACTIV)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		


KEY SHARE DATA

Share details as of October 28, 2025



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 154.20
MARKET CAPITALIZATION	EUR 1,569 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
STOCK MARKET SEGMENT	SDAX since October 2, 2024
DESIGNATED SPONSOR	Baader Bank AG ODDO BHF SE

SHAREHOLDER STRUCTURE



As of September 2025. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the "Guide to the DAX Equity Indices."